POLE and colorectal carcinoma: Our paper aims to showcase the effectiveness of nivolumab and ipilimumab in treating POLE-mutant CRC, as demonstrated by a rapid decrease in ctDNA, radiographic response, and normalization of CEA in this patient with EOCRC.